Baxter International Inc. Share Price Target ‘$43.83’, now 24.3% Upside Potential

DirectorsTalk Interviews

Baxter International Inc. which can be found using ticker (BAX) now have 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The range between the high target price and low target price is between $54.00 and $39.00 with the average share target price sitting at $43.83. (at the time of writing). Now with the previous closing price of $35.25 this is indicating there is a potential upside of 24.3%. It’s also worth noting that there is a 50 day moving average of $40.06 and the 200 moving average now moves to $38.68. The market capitalization for the company is 17.85B. The stock price for the company is currently $35.02 USD

The potential market cap would be $22,189,160,333 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $29.39 and a 3.54% return on assets.

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals, and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

Share on:
Find more news, interviews, share price & company profile here for:

    CLO income fund Volta Finance delivers 0.4% return in June, NAV at €7.46

    In June 2025, Volta Finance achieved a net performance of +0.4%, lifting its cumulative return since August 2024 to +11.2%, with both CLO debt and equity assets posting gains amid easing trade tensions and stable credit markets, and ending the month with a NAV of €7.46 per share.

    Thor Energy signs term sheet with Met1 for US project sale

    Thor Energy has agreed a term sheet to sell 75% of its US uranium and vanadium subsidiaries to Met1 for a £100,000 exclusivity fee and £1 million in stock, retaining a 25% interest.

    Global Opportunities Trust NAV at £110.7 m

    As at 30 June 2025, Global Opportunities Trust reported net assets of £110.7 m with equity investments representing 64.6 % of the portfolio. Top holdings include the AVI Japanese Special Situations Fund (12.9 %) and Volunteer Park Capital Fund (7.0 %).

    China-focussed UK stock FCSS reports 27% annual share price rise

    China’s stimulus drove economic recovery, with stock selection in Hesai Group, LexinFintech and VNET adding value despite underweights in Xiaomi, Xpeng and Tuhu, while over the 12 months to 30 June 2025 the Trust’s NAV rose 28.0% and its share price gained 27.3%, outperforming the reference index’s 23.4%.

    UK market a ‘rich pool of investment opportunities’, FSV Factsheet

    UK equities delivered modest gains in June, supported by prospects of BoE rate cuts and a more constructive tariff outlook, despite a mid‑month risk‑off following US and Israel strikes on Iranian sites and subsequent relief from a ceasefire.

    Fidelity Asian Values significantly outperforms its index over 1 year (LON:FAS)

    Over the 12 months to 30 June 2025, the Trust’s NAV rose 4.9%, outperforming its reference index which fell 0.1%, while the share price gained 6.9%. Stock selection was the key driver, with contrarian positions in China and Australia and picks in materials and consumer staples adding value, though an overweight in Indonesian small caps detracted.

      Search

      Search